ArticleFrontiers in oncology2019
PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.Cancer biology & medicine · 2024Trial
- Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion.Thoracic cancer · 2022Article
- Review
- Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.Thoracic cancer · 2020Article
- PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3.Frontiers in cell and developmental biology · 2020Article
- Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies.Frontiers in oncology · 2020Article
- Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.